The current manufacturer recommendation states that the clinician should not deploy the device if they are unable to advance a 0.014-inch guidewire across the plaque. Also, the procedure should not be attempted in patients suffering from coronary in-stent restenosis (ISR), though its successful off-label use for this entity has been previously described.